Loading…
Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model
Microbial secondary metabolites, which play a pivotal role in struggling with infectious diseases, are the new source for controlling bacterial contaminations and possess a strong antimicrobial potential. The present study is designed to evaluate the in vitro and in vivo bactericidal activities of p...
Saved in:
Published in: | ACS omega 2024-02, Vol.9 (7), p.8397-8404 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-a453t-fc7e2c3d13b9736debf78123ec9e3c2cafdd6fb4a2d561b045ca69f9fe1a951d3 |
container_end_page | 8404 |
container_issue | 7 |
container_start_page | 8397 |
container_title | ACS omega |
container_volume | 9 |
creator | Köksal Karayildirim, Çinel Şahiner, Aslı Çalişkan, Sennur Soylu, Fahri Emrah Gökhan, Aylin Eroğlu, Ebru Uyanikgil, Yiğit Karayildirim, Tamer |
description | Microbial secondary metabolites, which play a pivotal role in struggling with infectious diseases, are the new source for controlling bacterial contaminations and possess a strong antimicrobial potential. The present study is designed to evaluate the in vitro and in vivo bactericidal activities of prodigiosin against Staphylococcus aureus. For this purpose, Serratia marcescens was used to produce prodigiosin. Characterization of the prodigiosin was carried out using NMR. In addition, bioautographic detection of prodigiosin was detected by TLC. Antibacterial assays, in vivo epicutaneous infection tests, swap analyses, and histopathological examinations were determined. The results revealed that prodigiosin was detected by NMR and TLC. According to antimicrobial susceptibility tests, prodigiosin is an efficient bactericidal compound that demonstrated strong antibacterial activity toward S. aureus. In vivo, animal studies determined that the strong inhibition of S. aureus-caused epidermal infection occurs by prodigiosin at 48 h. Histopathological results showed that S. aureus + prodigiosin skin sections consist of improved and healthy tissues without any infection area compared with the S. aureus and control groups. The in vivo study verified the antibacterial results with swap analyses, and histopathological findings showed that prodigiosin is a promising microbial metabolite effective against S. aureus infection. This study proved that prodigiosin with excellent bioactivity exhibited antibacterial properties, which might possess massive potential for new therapeutic approaches using micro-organisms. |
doi_str_mv | 10.1021/acsomega.3c09522 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_348669a15a68416a91e63fe7789c9887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_348669a15a68416a91e63fe7789c9887</doaj_id><sourcerecordid>2932024624</sourcerecordid><originalsourceid>FETCH-LOGICAL-a453t-fc7e2c3d13b9736debf78123ec9e3c2cafdd6fb4a2d561b045ca69f9fe1a951d3</originalsourceid><addsrcrecordid>eNp1kk1v2zAMho1hw1p0ve806LhD0-nLsnQaiiJbA7TYYR9XgZaoTIFtZbIdoP9jP3hqkhbtYSeJ5MtHFMmqes_oJaOcfQI3ph7XcCkcNTXnr6pTLhu6YEKK18_uJ9X5OG4opUxprrl6W50ILWkthT6t_q7G1MEU03BBVh6HKYbojjYMnlwVTx9dTm2Ejix30M37KEmBfEeXBg_5ntzhBG3q4oQk5NSXSM5FBqSH7HB0OIxkV0wYyGogv-IukeU2unmCAdM8FmdAt8feJY_du-pNgG7E8-N5Vv38svxxfbO4_fZ1dX11uwBZi2kRXIPcCc9EaxqhPLah0YwLdAaF4w6C9yq0ErivFWuprB0oE0xABqZmXpxVqwPXJ9jYbY6l3HubINq9I-W1hTxF16EVUitlgNWgtGQKDEMlAjaNNs5o3RTW5wNrO7c9-vLlKUP3AvoyMsTfdp12llFdhqJZIXw8EnL6M-M42T6W1nXdoUmWG8Epl4rLIqUHaRnMOGYMT-8wah-Wwz4uhz0uR0n58Ly-p4THVSiCi4OgpNpNmvNQWv9_3j_VE8mm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2932024624</pqid></control><display><type>article</type><title>Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model</title><source>American Chemical Society (ACS) Open Access</source><source>PubMed Central</source><creator>Köksal Karayildirim, Çinel ; Şahiner, Aslı ; Çalişkan, Sennur ; Soylu, Fahri Emrah ; Gökhan, Aylin ; Eroğlu, Ebru ; Uyanikgil, Yiğit ; Karayildirim, Tamer</creator><creatorcontrib>Köksal Karayildirim, Çinel ; Şahiner, Aslı ; Çalişkan, Sennur ; Soylu, Fahri Emrah ; Gökhan, Aylin ; Eroğlu, Ebru ; Uyanikgil, Yiğit ; Karayildirim, Tamer</creatorcontrib><description>Microbial secondary metabolites, which play a pivotal role in struggling with infectious diseases, are the new source for controlling bacterial contaminations and possess a strong antimicrobial potential. The present study is designed to evaluate the in vitro and in vivo bactericidal activities of prodigiosin against Staphylococcus aureus. For this purpose, Serratia marcescens was used to produce prodigiosin. Characterization of the prodigiosin was carried out using NMR. In addition, bioautographic detection of prodigiosin was detected by TLC. Antibacterial assays, in vivo epicutaneous infection tests, swap analyses, and histopathological examinations were determined. The results revealed that prodigiosin was detected by NMR and TLC. According to antimicrobial susceptibility tests, prodigiosin is an efficient bactericidal compound that demonstrated strong antibacterial activity toward S. aureus. In vivo, animal studies determined that the strong inhibition of S. aureus-caused epidermal infection occurs by prodigiosin at 48 h. Histopathological results showed that S. aureus + prodigiosin skin sections consist of improved and healthy tissues without any infection area compared with the S. aureus and control groups. The in vivo study verified the antibacterial results with swap analyses, and histopathological findings showed that prodigiosin is a promising microbial metabolite effective against S. aureus infection. This study proved that prodigiosin with excellent bioactivity exhibited antibacterial properties, which might possess massive potential for new therapeutic approaches using micro-organisms.</description><identifier>ISSN: 2470-1343</identifier><identifier>EISSN: 2470-1343</identifier><identifier>DOI: 10.1021/acsomega.3c09522</identifier><identifier>PMID: 38405438</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS omega, 2024-02, Vol.9 (7), p.8397-8404</ispartof><rights>2024 The Authors. Published by American Chemical Society</rights><rights>2024 The Authors. Published by American Chemical Society.</rights><rights>2024 The Authors. Published by American Chemical Society 2024 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a453t-fc7e2c3d13b9736debf78123ec9e3c2cafdd6fb4a2d561b045ca69f9fe1a951d3</cites><orcidid>0000-0002-8431-1230</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsomega.3c09522$$EPDF$$P50$$Gacs$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsomega.3c09522$$EHTML$$P50$$Gacs$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27080,27924,27925,53791,53793,56762,56812</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38405438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Köksal Karayildirim, Çinel</creatorcontrib><creatorcontrib>Şahiner, Aslı</creatorcontrib><creatorcontrib>Çalişkan, Sennur</creatorcontrib><creatorcontrib>Soylu, Fahri Emrah</creatorcontrib><creatorcontrib>Gökhan, Aylin</creatorcontrib><creatorcontrib>Eroğlu, Ebru</creatorcontrib><creatorcontrib>Uyanikgil, Yiğit</creatorcontrib><creatorcontrib>Karayildirim, Tamer</creatorcontrib><title>Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model</title><title>ACS omega</title><addtitle>ACS Omega</addtitle><description>Microbial secondary metabolites, which play a pivotal role in struggling with infectious diseases, are the new source for controlling bacterial contaminations and possess a strong antimicrobial potential. The present study is designed to evaluate the in vitro and in vivo bactericidal activities of prodigiosin against Staphylococcus aureus. For this purpose, Serratia marcescens was used to produce prodigiosin. Characterization of the prodigiosin was carried out using NMR. In addition, bioautographic detection of prodigiosin was detected by TLC. Antibacterial assays, in vivo epicutaneous infection tests, swap analyses, and histopathological examinations were determined. The results revealed that prodigiosin was detected by NMR and TLC. According to antimicrobial susceptibility tests, prodigiosin is an efficient bactericidal compound that demonstrated strong antibacterial activity toward S. aureus. In vivo, animal studies determined that the strong inhibition of S. aureus-caused epidermal infection occurs by prodigiosin at 48 h. Histopathological results showed that S. aureus + prodigiosin skin sections consist of improved and healthy tissues without any infection area compared with the S. aureus and control groups. The in vivo study verified the antibacterial results with swap analyses, and histopathological findings showed that prodigiosin is a promising microbial metabolite effective against S. aureus infection. This study proved that prodigiosin with excellent bioactivity exhibited antibacterial properties, which might possess massive potential for new therapeutic approaches using micro-organisms.</description><issn>2470-1343</issn><issn>2470-1343</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>N~.</sourceid><sourceid>DOA</sourceid><recordid>eNp1kk1v2zAMho1hw1p0ve806LhD0-nLsnQaiiJbA7TYYR9XgZaoTIFtZbIdoP9jP3hqkhbtYSeJ5MtHFMmqes_oJaOcfQI3ph7XcCkcNTXnr6pTLhu6YEKK18_uJ9X5OG4opUxprrl6W50ILWkthT6t_q7G1MEU03BBVh6HKYbojjYMnlwVTx9dTm2Ejix30M37KEmBfEeXBg_5ntzhBG3q4oQk5NSXSM5FBqSH7HB0OIxkV0wYyGogv-IukeU2unmCAdM8FmdAt8feJY_du-pNgG7E8-N5Vv38svxxfbO4_fZ1dX11uwBZi2kRXIPcCc9EaxqhPLah0YwLdAaF4w6C9yq0ErivFWuprB0oE0xABqZmXpxVqwPXJ9jYbY6l3HubINq9I-W1hTxF16EVUitlgNWgtGQKDEMlAjaNNs5o3RTW5wNrO7c9-vLlKUP3AvoyMsTfdp12llFdhqJZIXw8EnL6M-M42T6W1nXdoUmWG8Epl4rLIqUHaRnMOGYMT-8wah-Wwz4uhz0uR0n58Ly-p4THVSiCi4OgpNpNmvNQWv9_3j_VE8mm</recordid><startdate>20240220</startdate><enddate>20240220</enddate><creator>Köksal Karayildirim, Çinel</creator><creator>Şahiner, Aslı</creator><creator>Çalişkan, Sennur</creator><creator>Soylu, Fahri Emrah</creator><creator>Gökhan, Aylin</creator><creator>Eroğlu, Ebru</creator><creator>Uyanikgil, Yiğit</creator><creator>Karayildirim, Tamer</creator><general>American Chemical Society</general><scope>N~.</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8431-1230</orcidid></search><sort><creationdate>20240220</creationdate><title>Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model</title><author>Köksal Karayildirim, Çinel ; Şahiner, Aslı ; Çalişkan, Sennur ; Soylu, Fahri Emrah ; Gökhan, Aylin ; Eroğlu, Ebru ; Uyanikgil, Yiğit ; Karayildirim, Tamer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a453t-fc7e2c3d13b9736debf78123ec9e3c2cafdd6fb4a2d561b045ca69f9fe1a951d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Köksal Karayildirim, Çinel</creatorcontrib><creatorcontrib>Şahiner, Aslı</creatorcontrib><creatorcontrib>Çalişkan, Sennur</creatorcontrib><creatorcontrib>Soylu, Fahri Emrah</creatorcontrib><creatorcontrib>Gökhan, Aylin</creatorcontrib><creatorcontrib>Eroğlu, Ebru</creatorcontrib><creatorcontrib>Uyanikgil, Yiğit</creatorcontrib><creatorcontrib>Karayildirim, Tamer</creatorcontrib><collection>American Chemical Society (ACS) Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>ACS omega</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Köksal Karayildirim, Çinel</au><au>Şahiner, Aslı</au><au>Çalişkan, Sennur</au><au>Soylu, Fahri Emrah</au><au>Gökhan, Aylin</au><au>Eroğlu, Ebru</au><au>Uyanikgil, Yiğit</au><au>Karayildirim, Tamer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model</atitle><jtitle>ACS omega</jtitle><addtitle>ACS Omega</addtitle><date>2024-02-20</date><risdate>2024</risdate><volume>9</volume><issue>7</issue><spage>8397</spage><epage>8404</epage><pages>8397-8404</pages><issn>2470-1343</issn><eissn>2470-1343</eissn><abstract>Microbial secondary metabolites, which play a pivotal role in struggling with infectious diseases, are the new source for controlling bacterial contaminations and possess a strong antimicrobial potential. The present study is designed to evaluate the in vitro and in vivo bactericidal activities of prodigiosin against Staphylococcus aureus. For this purpose, Serratia marcescens was used to produce prodigiosin. Characterization of the prodigiosin was carried out using NMR. In addition, bioautographic detection of prodigiosin was detected by TLC. Antibacterial assays, in vivo epicutaneous infection tests, swap analyses, and histopathological examinations were determined. The results revealed that prodigiosin was detected by NMR and TLC. According to antimicrobial susceptibility tests, prodigiosin is an efficient bactericidal compound that demonstrated strong antibacterial activity toward S. aureus. In vivo, animal studies determined that the strong inhibition of S. aureus-caused epidermal infection occurs by prodigiosin at 48 h. Histopathological results showed that S. aureus + prodigiosin skin sections consist of improved and healthy tissues without any infection area compared with the S. aureus and control groups. The in vivo study verified the antibacterial results with swap analyses, and histopathological findings showed that prodigiosin is a promising microbial metabolite effective against S. aureus infection. This study proved that prodigiosin with excellent bioactivity exhibited antibacterial properties, which might possess massive potential for new therapeutic approaches using micro-organisms.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>38405438</pmid><doi>10.1021/acsomega.3c09522</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8431-1230</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2470-1343 |
ispartof | ACS omega, 2024-02, Vol.9 (7), p.8397-8404 |
issn | 2470-1343 2470-1343 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_348669a15a68416a91e63fe7789c9887 |
source | American Chemical Society (ACS) Open Access; PubMed Central |
title | Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A28%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isolation,%20Identification,%20and%20Antimicrobial%20Evaluation%20of%20Secondary%20Metabolite%20from%20Serratia%20marcescens%20via%20an%20In%20Vivo%20Epicutaneous%20Infection%20Model&rft.jtitle=ACS%20omega&rft.au=Ko%CC%88ksal%20Karayildirim,%20C%CC%A7inel&rft.date=2024-02-20&rft.volume=9&rft.issue=7&rft.spage=8397&rft.epage=8404&rft.pages=8397-8404&rft.issn=2470-1343&rft.eissn=2470-1343&rft_id=info:doi/10.1021/acsomega.3c09522&rft_dat=%3Cproquest_doaj_%3E2932024624%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a453t-fc7e2c3d13b9736debf78123ec9e3c2cafdd6fb4a2d561b045ca69f9fe1a951d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2932024624&rft_id=info:pmid/38405438&rfr_iscdi=true |